Aurinia's second quarter looked like a single-product lupus drug stepping on the gas. Total revenue of $83.2 million was 19% above the year-ago $70.0 million; net product sales of LUPKYNIS hit $79.4 million, up 19% on more cartons moving to two U.S. specialty pharmacies; GAAP net income reached $37.4 million, up 74%; and operating cash flow for the first half ran at $85.1 million, up 87% from the depressed $45.5 million a year ago. The balance sheet closed the quarter with $443.1 million of cash and short-term investments, against a finance lease of roughly $60 million and no traditional debt. Reiterated full-year guidance calls for $315–325 million of revenue and $305–315 million of net product sales, an 11–15% top-line increase that is now comfortably ahead of the run-rate through six months.
The load-bearing tell of the quarter was not the LUPKYNIS line. It was a small asset acquisition of Kezar Life Sciences, closed on May 11, for total consideration of $55.5 million in cash plus a contingent value right. That single transaction added aritinercept - a dual BAFF/APRIL inhibitor now in clinical development across four autoimmune indications - alongside a much smaller lupus drug called zetomipzomib wrapped in milestone-linked CVR consideration. The Kezar deal reframes the equity from a one-asset franchise into a one-asset franchise plus an early-stage pipeline option, paid for entirely out of cash that was already on the balance sheet, with the buyback authorization still at $86.6 million of remaining capacity. The question the second half answers is whether the LUPKYNIS engine can fund the platform expansion without diluting shareholders - and whether the aritinercept program hits a credibly timed clinical milestone by the end of next year.